Dr. Song on Zanubrutinib Activity in Relapsed/Refractory MCL
Yuqin Song, MD, PhD, chief physician and deputy director of the Lymphoma Department at Peking University Cancer Hospital, Beijing, China, discusses the updated data from the phase II trial evaluating the efficacy of zanubrutinib (BGB-3111-206) in patients with relapsed/refractory mantle cell lymphoma.
Yuqin Song, MD, PhD, chief physician and deputy director of the Lymphoma Department at Peking University Cancer Hospital, Beijing, China, discusses the updated data from the phase II trial evaluating the efficacy of zanubrutinib (BGB-3111-206) in patients with relapsed/refractory mantle cell lymphoma (MCL).
The updated data included an overall response rate of 84.7%, with 65 patients (76.5%) achieving a complete response, says Song. The median duration of response was 14.0 months (range, 2.32‐14.0 months) and the median progression-free survival was 16.7 months (range 0.0+ to 16.7+ months). Responses appeared to be durable and the safety profile remained consistent with previous reported data.
The study, conducted in China, enrolled 86 adult patients with MCL who had received 1 to 4 prior treatment regimens. They were treated with 160 mg twice daily of zanubrutinib until disease progression or unacceptable toxicity. In January 2019, the FDA granted zanubrutinib a breakthrough designation based on the activity of the BTK inhibitor for the treatment of patients with MCL.
